INCY Incyte Corp

Price (delayed)

$64.34

Market cap

$14.45B

P/E Ratio

19.32

Dividend/share

N/A

EPS

$3.33

Enterprise value

$11.13B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights
INCY's net income has soared by 130% year-on-year and by 25% since the previous quarter
INCY's EPS has soared by 128% YoY and by 25% QoQ
The company's quick ratio fell by 12% YoY and by 7% QoQ

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
224.54M
Market cap
$14.45B
Enterprise value
$11.13B
Valuations
Price to book (P/B)
2.68
Price to sales (P/S)
3.83
EV/EBIT
10.9
EV/EBITDA
10.06
EV/Sales
2.95
Earnings
Revenue
$3.77B
EBIT
$1.02B
EBITDA
$1.11B
Free cash flow
$790.77M
Per share
EPS
$3.33
Free cash flow per share
$3.52
Book value per share
$24.03
Revenue per share
$16.78
TBVPS
$30.57
Balance sheet
Total assets
$7.14B
Total liabilities
$1.74B
Debt
$32.61M
Equity
$5.39B
Working capital
$3.45B
Liquidity
Debt to equity
0.01
Current ratio
3.47
Quick ratio
3.29
Net debt/EBITDA
-3
Margins
EBITDA margin
29.4%
Gross margin
93.1%
Net margin
19.8%
Operating margin
18.3%
Efficiency
Return on assets
11.2%
Return on equity
14.7%
Return on invested capital
53%
Return on capital employed
17.8%
Return on sales
27.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
0.53%
1 week
5.94%
1 month
2.63%
1 year
5.34%
YTD
2.47%
QTD
6.14%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$3.77B
Gross profit
$3.51B
Operating income
$687.65M
Net income
$745.44M
Gross margin
93.1%
Net margin
19.8%
INCY's net income has soared by 130% year-on-year and by 25% since the previous quarter
The net margin has soared by 113% year-on-year and by 22% since the previous quarter
Incyte's operating income has increased by 41% YoY and by 11% from the previous quarter
INCY's operating margin is up by 30% year-on-year and by 9% since the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
P/E
19.32
P/B
2.68
P/S
3.83
EV/EBIT
10.9
EV/EBITDA
10.06
EV/Sales
2.95
INCY's EPS has soared by 128% YoY and by 25% QoQ
INCY's P/E is 30% below its last 4 quarters average of 27.3
The stock's price to book (P/B) is 49% less than its 5-year quarterly average of 5.2
INCY's equity is up by 21% year-on-year and by 3.9% since the previous quarter
INCY's P/S is 35% below its 5-year quarterly average of 5.9 but 3% above its last 4 quarters average of 3.7
Incyte's revenue has increased by 9% YoY

Efficiency

How efficient is Incyte business performance
The ROE has soared by 93% YoY and by 19% from the previous quarter
INCY's return on assets has surged by 93% year-on-year and by 18% since the previous quarter
INCY's ROS has soared by 83% YoY and by 20% QoQ
The ROIC has soared by 66% YoY and by 15% from the previous quarter

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
INCY's total liabilities is up by 30% year-on-year and by 9% since the previous quarter
Incyte's total assets has increased by 23% YoY and by 5% from the previous quarter
The debt is 99% smaller than the equity
INCY's equity is up by 21% year-on-year and by 3.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.